Our Milestones

Design and testing of the Scoliosis Support Rod System prototypes.
US Patent issued December 2023
Nasca R & D LLC formed March 2024
Validation of the ability of SSRS to elongate with simulated spine growth using an Instron testing machine done by Ali Kiapour at Harvard /Mass General Department of Neurosurgery. August 2024
Implantation of the SSRS device in two sheep at Colorado State to verify that the device will lengthen with spine growth and maturation and remain fixed to the spine during rapid growth. April and May of 2025
Design and preliminary testing of Trans-osseous Vertebral Fixation for Interbody Cages 2022 by Andy L. Freeman PhD

Phase I

Funds needed for 510 (k) for SSRS

Use of Funds

Phase II

Clinical Study

100 to 200 patients partner with Shriners or other Children’s hospitals once we receive FDA clearance. Clinical trial duration 36 months.

Use of Funds

1. Collaboration

At Nasca R&D, we believe that the most transformative innovations are born from diverse perspectives and partnerships. That’s why we tailor our solutions to the specific needs of our patients, ensuring that their outcomes align with their objectives

2. Research

Our dedicated team of scientists, engineers, and researchers are focused on providing a product that will power deformity correction during spine growth and maturation and preserve spine motion.

Why Choose NASCA R&D LLC?

Innovation-Driven

We pride ourselves on our ability to turn ideas into revolutionary solutions.

Expertise Across Disciplines:

Our diverse expertise ensures a comprehensive approach to challenges.

Commitment to Quality:

Every project we undertake reflects our dedication to excellence and precision.

Summary

SSRS is a unique device powered by the patient’s growth.
We have an experienced, talented and knowledgeable team.
There are 300,000 patients that have surgery for scoliosis each year in the USA.
There is a growing market of 70,000 to 100,000 patients for motion preservation in the adolescent scoliosis population.
We predict that your investment will multiply 3 to 5 fold based on projections of sales staring in 2027

Our Milestones

Design and testing of the Scoliosis Support Rod System prototypes.

US Patent issued December 2023

Nasca R & D LLC formed March 2024

Validation of the ability of SSRS to elongate with simulated spine growth using an Instron testing machine done by Ali Kiapour at Harvard /Mass General Department of Neurosurgery. August 2024

Implantation of the SSRS device in two sheep at Colorado State to verify that the device will lengthen with spine growth and maturation and remain fixed to the spine during rapid growth. April and May of 2025

Design and preliminary testing of Trans-osseous Vertebral Fixation for Interbody Cages 2022 by Andy L. Freeman PhD

Phase I

Funds needed for 510 (k) for SSRS

Use of Funds

Phase II

Clinical Study

100 to 200 patients partner with Shriners or other Children’s hospitals once we receive FDA clearance. Clinical trial duration 36 months.

Use of Funds

1. Collaboration

At Nasca R&D, we believe that the most transformative innovations are born from diverse perspectives and partnerships. That’s why we tailor our solutions to the specific needs of our patients, ensuring that their outcomes align with their objectives

2. Research

Our dedicated team of scientists, engineers, and researchers are focused on providing a product that will power deformity correction during spine growth and maturation and preserve spine motion.

Why Choose NASCA R&D LLC?

Innovation-Driven

Expertise Across Disciplines:

Commitment to Quality:

Summary

SSRS is a unique device powered by the patient’s growth.

We have an experienced, talented and knowledgeable team.

There are 300,000 patients that have surgery for scoliosis each year in the USA.

There is a growing market of 70,000 to 100,000 patients for motion preservation in the adolescent scoliosis population.

We predict that your investment will multiply 3 to 5 fold based on projections of sales staring in 2027